Ten-year clinical laboratory follow-up after application of a symptom-based therapeutic strategy to patients with severe chronic aortic regurgitation of predominant rheumatic etiology  by Tarasoutchi, Flavio et al.
Valvular Heart Disease
Ten-Year Clinical Laboratory Follow-Up
After Application of a Symptom-Based
Therapeutic Strategy to Patients With Severe Chronic
Aortic Regurgitation of Predominant Rheumatic Etiology
Flavio Tarasoutchi, MD, Max Grinberg, MD, Guilherme S. Spina, MD, Roney O. Sampaio, MD,
Luı´s F. Cardoso, MD, Eduardo G. Rossi, MD, Pablo Pomerantzeff, MD, Francisco Laurindo, MD,
Prota´sio L. da Luz, MD, FACC, Jose´ Antoˆnio F. Ramires, MD, FACC
Sa˜o Paulo, Brazil
OBJECTIVES This study was designed to assess the feasibility and the long-term results of a symptom-based
strategy of aortic valve replacement in a Brazilian population with predominant rheumatic
etiology.
BACKGROUND Optimal criteria for valve replacement in aortic regurgitation (AR) are still not entirely clear.
The appearance of symptoms is an indication for surgery, but may be associated with
myocardial damage. Although cardiac imaging data have provided a safer guide for such
decisions, the use of symptom-based surgical indication has not been validated and might
conceivably be better in populations with predominant rheumatic etiology and younger age.
METHODS Echocardiography and rest-exercise radionuclide ventriculography were performed in 75
patients with severe AR, age 28  9 years, over a period of 10  0.69 years. Thirty-seven
patients developed symptoms and underwent aortic valve replacement surgery within six
months. Thirty-eight patients remained asymptomatic and were managed medically.
RESULTS Survival was 100% in asymptomatic patients and 82% in symptomatic. Surgical treatment
caused marked ventricular remodeling, with ventricular diameter involution and an improve-
ment of rest-exercise ejection fraction percent variation. Multivariate analysis showed that the
probability of developing symptoms within 10 years was 58% for a patient with a left
ventricular end-diastolic diameter 70 mm and 76% for a patient with left ventricular
end-systolic (LVESD) 50 mm. Logistic regression identified LVESD and age as the most
predictive and specific, but not sensitive, indicators of symptom development.
CONCLUSIONS Application of a standardized therapeutic strategy to patients with severe AR and predom-
inant rheumatic etiology resulted in 90.6% survival after 10 years of follow-up. (J Am Coll
Cardiol 2003;41:1316–24) © 2003 by the American College of Cardiology Foundation
Optimal criteria for valve replacement in aortic regurgita-
tion (AR) are still not entirely clear (1–3). The natural
history of AR is characterized by a long asymptomatic
period during which significant eccentric left ventricular
(LV) hypertrophy as well as large vessel remodeling take
place as an adaptive response to pressure-volume overload
(4–7).
See page 1325
The appearance of symptoms is generally viewed as an
exhaustion of such adaptive mechanisms, which may lead to
permanent damage to cardiomyocyte structure and function
and/or alterations of the extracellular matrix (8,9). Such
damage can preclude recovery of myocardial function after
valve replacement (10,11).
During the past two decades (12–18), prognostic assess-
ment studies based primarily on LV dimensions and/or
systolic function have led to echocardiographic-based
guidelines to define the ideal timing of surgical intervention,
designed to interrupt the natural history of AR while
minimizing the exposure to the complications of valvular
prosthesis. Clinical decisions in such cases, however, remain
controversial (19).
In Brazil, and likely in many other communities in which
valvular heart disease is widely prevalent, the major etiology
of AR is rheumatic fever. Such patients are much younger
than the average patient covered by guidelines mentioned
earlier and are more likely to reach the suggested cutoff
values for LV size and function much earlier in the course of
their disease (18). As long as myocardial function is signif-
icantly affected by age, the recovery of myocardial function
after AR correction might conceivably be better in younger
patients. In this situation, the echocardiographic variables
defined as class IIa indication for AR in the guidelines
issued, for example, by the American College of Cardiology
(ACC) and American Heart Association (AHA) (19) might
lead to early exposure to the complications of valvular
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prosthesis without concomitant gain in the recovery of LV
function. Indeed, it has been noted previously that many
such patients operated soon after the onset of symptoms are
capable of a full short-term recovery despite left ventricular
end-systolic diameters (LVESDs) well above the cutoff of
55 mm (18,20,21). This is an indication that these patients
might tolerate considerably larger increases in their LV size
without detectable compromise in later function. The long-
term results of such an approach, however, have not been
assessed in our population. In addition to a welcome
positive economic impact, the possibility of a delayed
intervention could improve the long-term patient outcome
because of decreased morbidity/mortality associated with
valvular prosthesis and reoperations. The present study
prospectively assessed the feasibility of a symptom-based
indication for aortic valve replacement in severe chronic AR
by examining the 10-year follow-up of a cohort of 75
patients in whom operation was indicated at the onset of
clinical symptoms rather than based on the degree of LV
enlargement.
METHODS
Study population. Severe chronic AR was defined accord-
ing to the modified criteria of Spagnuolo et al. (22), which
demanded a cardiothoracic index 0.50, electrocardio-
graphic evidence of LV hypertrophy, a pulse pressure 80
mm Hg, diastolic arterial pressure 60 mm Hg, and
Doppler echocardiography, which allows one to define the
degree of AR. Seventy-five consecutive asymptomatic pa-
tients who met these criteria between January 1988 and
December 1989 were prospectively enrolled and followed as
outpatients at the Heart Institute (InCor) of the University
of Sa˜o Paulo. Exclusion criteria consisted of patient age
18 or 60 years, coexisting AF, or any cardiac condition
other than AR. Thirty percent of the patients were receiving
drugs, including digitalis, diuretics, or both. Asymptomatic
patients did not receive any arterial or venous vasodilator
during the study.
Informed consent was obtained for each patients and the
study was approved by the local scientific/ethics committee.
Radioisotopic ventriculography. Multiple-gated acquisi-
tion radioisotopic ventriculography was performed at rest
and during exercise. All medications including diuretics
were interrupted for at least three days before the test.
Images were obtained with the patients seated at a 45°
angle in the left anterior oblique projection for optimal
distinction between the LV and right ventricle. Images were
acquired by manually selected areas of interest in the LV, at
maximal diastole and systole, after subtracting background
radiation. Exercise was performed on a bicycle and followed
the Heart Institute protocol (18). A starting load of 25 W
was increased by 25 W every 4 min. The speed was kept
constant at 70 rotations per min. The extent of exercise was
guided by generalized fatigue or the appearance of the first
sign of dyspnea. Cardiac rhythm and blood pressure were
monitored throughout the test. Images acquired during
exercise were overlaid on those obtained at rest. The left
ventricular ejection fraction (LVEF) at rest, LVEF at
maximal exercise, and total effort time were recorded. A
normal exercise response was defined as an increase in the
LVEF of 5% or more from rest to maximal exercise (17,23).
Echocardiography. Echocardiographic examinations were
performed using either an Aloka SSD, model 860, with a
2.5 MHz transducer (Aloka, Japan) or an Aloka SSD,
model 725, with 2 and 3 MHz transducers. Interpretation
followed the American Society of Echocardiography stan-
dards (24). The following LV variables were evaluated:
end-diastolic diameter (LVEDD) in mm; LVESD in mm,
and shortening fraction (SF). The cutoff values used for data
analysis were drawn from well-accepted guidelines previ-
ously defined in the literature (12,13,15,19).
Follow-up. Once enrolled, each patient underwent com-
plete clinical and cardiologic examination and was then
followed for at least 120 months. Clinical examinations
were repeated every 6 months and noninvasive cardiac tests
every 12 months. Both procedures were performed earlier if
symptoms occurred. Cardiac assessment included exercise
testing, chest roentgenogram, resting echocardiography,
and rest-exercise radionuclide ventriculography.
Particular attention was paid to assess the etiology of AR,
which was determined on the basis of clinical history as well
as echocardiographic evidence of mitral valve thickening in
the majority of rheumatic patients, although none had the
mitral stenosis and morphology of valves removed from
patients during surgery.
Some patients remained asymptomatic throughout the
120-month study. Asymptomatic patients were defined as
those not exhibiting symptoms of dyspnea, chest pain,
dizziness, syncope, or extreme effort dyspnea. Symptomatic
patients developed symptoms of congestive heart failure,
such as dyspnea during habitual physical activities and at
rest, chest pain, easier-than-normal fatigue, and/or syncope.
Patients who developed symptoms were immediately sched-
uled for aortic valve surgery, which was performed within
the ensuing six months. Patients who underwent valve
replacement were followed postoperatively.
The minimal follow-up period was 120 months. Com-
parisons between patients remaining asymptomatic and
Abbreviations and Acronyms
ACC  American College of Cardiology
AHA  American Heart Association
AR  aortic regurgitation
EF r-ex  rest-exercise variation in left ventricular
ejection fraction
FC  functional class
LV  left ventricular
LVEDD  left ventricular end-diastolic diameter
LVEF  left ventricular ejection fraction
LVESD  left ventricular end-systolic diameter
SF  shortening fraction
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developing symptoms were performed at the beginning of
the study, at the onset of symptoms, and at the final
evaluation. Preoperative cardiac catheterization was per-
formed in all patients, and macro/microscopic examination
of all extracted aortic valves was performed.
Statistical analysis. Statistical analysis was performed with
SAS software. Significance was defined at the 0.05 level.
The mean  SD is reported for quantitative variables and
absolute and relative frequency for qualitative variables.
Both the paired and unpaired Student t tests were used.
Qualitative data were compared using the equivalence of
proportions hypothesis, the chi-square test or, when this
was limited, Fisher exact test (25). Multivariate profile
analysis (26,27) was used to analyze changes in echocardi-
ography and radioisotopic ventriculography data during
follow-up.
Factors predictive of specific events were analyzed
through a logistic regression model. The time interval to the
occurrence of such specific events was analyzed through
Kaplan-Meier curve and compared by log-rank tests.
RESULTS
Clinical follow-up. The minimum follow-up period was
10 years and the average follow-up period was 10.42 0.69
years.
Thirty-eight patients (50.6%) remained asymptomatic
throughout the follow-up; all such patients were alive at the
Figure 1. Clinical evolution of the 75 patients throughout the study, including outcomes.
Figure 2. Survival of the groups over the years. The survival was 100% in the asymptomatic group and 82% in the symptomatic group.
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end of the study. The other 37 patients (49.4%) constituted
the symptomatic group (Fig. 1). Of these patients, 30
became asymptomatic after surgical correction of the aortic
valve. Thus, symptomatic patients can be divided in three
clinical phases: an initial asymptomatic period, a symptom-
atic surgical period, and a postoperative period. Therefore,
at the end of that period, 68 (90.6%) of the 75 patients were
alive and asymptomatic (Fig. 2). Table 1 displays baseline
characteristics of the patients
The average time from study enrollment to the develop-
ment of symptoms was 4.6 1 year and mean postoperative
follow-up period 5.2  1.3 years. The reported symptoms
were dyspnea or intolerance to effort (56%), angina (28%),
and syncope (2%).
Laboratory parameters. Table 2 and Figure 3 show that
there were significant differences (p  0.05) in the mean
LVEDD, LVESD, SF, LVEF, and the rest-exercise vari-
ation in LVEF (EF r-ex) between groups at the beginning
of the study (baseline). The LVEDD did not significantly
change between baseline and final assessment in asymptom-
atic patients. However, significant changes (p  0.05) in
other parameters of LV function (LVESD, SF, LVEF, and
EF r-ex) occurred. In the symptomatic patients, there was
marked remodeling of the LV after surgery, with a signifi-
cant (p  0.0001) reduction in both LVESD and LVEDD
and an increase in the EF r-ex.
Initially, 50% of the asymptomatic patients had LVEDD
70 mm, and 15.8% had LVESD 50 mm. At the end of
the study, 52.7% patients had LVEDD70 mm (p ns vs.
baseline values, chi-square test) and 47.3% had LVESD
50 mm (p  0.021 vs. baseline values) (Tables 3 and 4).
In the symptomatic patients, there was initially higher
prevalences of LVEDD 70 mm (73%, p  0.0006 vs.
asymptomatic group) and LVESD 50 mm (51.3%, p 
0.0006 vs. asymptomatic group). In the symptomatic pa-
tients (91.8%) undergoing surgery there was marked de-
crease in LV size, so that at the end of the study, only 10%
of patients in this group had LVEDD 70 mm (p 
0.0001 vs. baseline) and only 10% had LVESD 50 mm (p
 0.0001 vs. baseline) (Tables 3 and 4).
We observed no increase in diameters or reductions in
systolic performance indexes at the time patients became
symptomatic (Fig. 3).
Systolic LV was also lower in symptomatic patients at the
beginning of the study (5.4% patients with SF 0.25 vs.
none of the asymptomatic patients, p 0.04). At the end of
the study, 5.3% of the asymptomatic patients and 16.7% of
the symptomatic patients had SFs 0.25. Overall, the SF
remained stable in the symptomatic patients (p  ns) but
significantly changed over time in asymptomatic ones (p 
0.0029) (Table 5, Fig. 3).
An analogous behavior was observed for the LVEF at rest
(Table 6, Fig. 3), which decreased from average of 0.64 to
0.59 (p  0.0005) in asymptomatic patients.
We observed that of the 27 patients who had LVEDD
75 mm or LVESD 55 mm (Tables 3 and 4), 20 needed
surgery and 7 remained asymptomatic. All seven with
LVEDD 75 mm or LVESD 55 mm who remained
asymptomatic had normal ventricular function at the end of
the study.
The rest-exercise percentile variation of the LVEF (EF
r-ex) was 0.05 at the initial (baseline) evaluation in 28.6%
of the symptomatic patients and 42.7% of the asymptomatic
patients (p  0.0972). After surgical treatment, at the final
evaluation, 63.3% of the symptomatic patients had a
LVEF 0.05, a significant (p  0.0001) change between
evaluations. In asymptomatic patients, the LVEF re-
mained stable over time (p  0.0976) (Table 7).
Surgical follow-up. Thirty-five aortic prostheses were im-
planted in 33 initial operations and 2 re-operations, includ-
ing 31 bioprostheses (80.5%) and 4 metallic prostheses
(11%). A conservative technique was used to repair the
aortic valve in one patient. Two patients required re-
operation after 60 and 65 months, respectively. Nine pa-
Table 1. General Data at Baseline
Total
(n  75)
Symptomatic
(n  37)
Asymptomatic
(n  38) p Value
Age (yrs) 28  9 32  11 25  5 0.001*
Male gender (%) 76 75 76 0.948†
Heart rate (beats/min) 72  12 72  13 73  11 0.750*
SAP (mm Hg) 148  20 145  22 151  18 0.230*
DAP (mm Hg) 42  27 43  35 41  16 0.762*
Cardiothoracic index 0.54  0.03 0.55  0.03 0.54  0.03 0.124*
Rheumatic etiology (%) 93 91 94 0.674†
Time of diagnosis (yrs) 5.8  3.4 5.8  2.1 5.8  4.4 0.997*
*Student’s test; †Chi-square test.
DAP  diastolic arterial pressure; SAP  systolic arterial pressure.
Table 2. Baseline and Final Laboratory Parameters
Variables
Symptomatic Asymptomatic
Baseline Final Baseline Final
LVESD (mm) 51  8 37  7* 45  5† 48  4*
LVEDD (mm) 76  9 55  8* 69  6† 71  6
SF 0.32  0.05 0.32  0.05 0.34  0.04† 0.31  0.04*
LVEF 0.60  0.05 0.61  0.08 0.64  0.05† 0.59  0.06*
EF r-ex 1.2  9 9  12* 3.5  9 1.1  8
*p  0.05 baseline vs. final evaluations, profile analysis; †p  0.05 between groups at
baseline profile analysis.
LVEDD  left ventricular end-diastolic diameter; LVEF  left ventricular
ejection fraction; LVESD  left ventricular end-systolic diameter; SF  shortening
fraction; EF r-ex: percentile variation of the rest-exercise LVEF.
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Figure 3. Evolution of left ventricular end-systolic diameter, left ventricular end-diastolic diameter, shortening fraction, left ventricular ejection fraction
(LVEF), and percentile variation of the rest-exercise ejection fraction in the symptomatic group and asymptomatic group over time. For symptomatic group,
four years follow-up was preoperative phase.
1320 Tarasoutchi et al. JACC Vol. 41, No. 8, 2003
10-Year Follow-Up of Chronic AR April 16, 2003:1316–24
tients had mild dysfunction of the bioprosthesis at the end
of the study and were in functional class (FC) I/II. Six
prosthesis-related complications occurred during the late
postoperative period.
Deaths. Three patients died while awaiting surgery; one of
them had refused-surgery, FC III heart failure and one had
FC II and syncope (Fig. 1, Table 8). There was no
immediate surgical mortality (Table 9).
The medium interval between surgery and death was 1.97
 1.18 years. All four patients were asymptomatic at the
time of their last evaluation. One patient with a metallic
prosthesis developed acute thrombosis and died. The re-
maining five complications involved bioprostheses and con-
sisted of two cases of fatal endocarditis and three sponta-
neous ruptures. Two of them had favorable outcomes after
repeated surgery, and one patient died. The patients who
died had ventricular diameters and systolic function similar
to asymptomatic survivors (Table 9).
Logistic regression. Univariate analysis identified rest
LVEDD (p 0.0015), rest LVESD (p 0.0003), SF (p
0.0384), LVEF at rest (p  0.0054), EF r-ex (p 
0.0034), and age (p  0.0030) as predictors of symptom
development. These variables were then evaluated through a
logistic regression model, with a stepwise selection process
to obtain risk factors predictive of symptoms. Results from
this multivariate analysis suggest that the LVESD at rest (p
 0.0001) and age (p  0.0003) are the best predictors of
symptoms.
The probability that a patient with an initial LVEDD
70 mm became symptomatic after 10 years was 58%, with
an odds ratio of 2.70, sensitivity 73.0%, specificity 50.0%,
and accuracy 61.3%. The probability that a patient with an
initial LVESD50 mm became symptomatic after 10 years
was 76%, with an odds ratio of 5.63, sensitivity 51.4%,
specificity 84.2%, and accuracy 68.0%.
DISCUSSION
Clinical follow-up. During the 1970s, Spagnuolo et al.
(22) proposed predictive clinical criteria for the natural
evolution of AR. Further studies suggested specific values
for echocardiographic as prognostic indication; for example,
indexes of poor postsurgical results include an LVEDD
70 mm, LVESD 55 mm, SF 0.25, final systolic
volume 90 ml/m2, LVEF 0.50, and LV radius-
thickness ratio 3.8 (7–16).
The clinical follow-up of patients with chronic AR at our
institution (18) for 36 months suggested a different view
from that reported by Henry et al. (12,13). Results showed
that the use of symptoms as a guide to the transition from
clinical to surgical treatment was appropriate. Although the
LVEDD and LVESD were 70 mm and 55 mm,
respectively, the postoperative outcome of most patients was
favorable. One explanation for the divergent findings be-
tween our study and that of Henry et al. (12,13) is that they
used an older population with significantly fewer rheumatic
patients.
In contrast, the prevalence of a rheumatic etiology of AR
in our patients (92%) was nearly three times higher than
that reported in other series, which averaged 30%. Further-
more, the mean age of patients in the present study (30
years) was nearly half of that (55 years) previously reported
in analogous reports series (28–30).Table 4. Distribution of End-Systolic Diameters at the Baseline
and Final Evaluations
LVESD
Symptomatic Asymptomatic
Baseline Final Baseline Final
n n n n
 40 (mm) 1 20 3 2
40–49 (mm) 17 7 29 18
50–54 (mm) 6 1 5 13
55 (mm) 13 2 1 5
Total 37* 30* 38 38
*The difference reflects the seven patients who died.
LVESD  left ventricular end-systolic diameter.
Table 6. Distribution of LVEF at the Baseline and
Final Evaluations
LVEF
Rest
Symptomatic Asymptomatic
Baseline Final Baseline Final
n n n n
 0.50 2 3 0 1
 0.50 34 27 38 37
Total 36* 30† 38 38
*One patient was unable to perform the test at the baseline evaluation; †The difference
reflects the seven patients who died.
LVEF  left ventricular ejection fraction.
Table 3. Distribution of End-Diastolic Diameters at the
Baseline and Final Evaluations
LVEDD
Symptomatic Asymptomatic
Baseline Final Baseline Final
n n n n
 60 (mm) 0 21 1 0
60–69 (mm) 10 6 18 18
70–74 (mm) 7 1 12 8
75 (mm) 20 2 7 12
Total 37* 30* 38 38
*The difference reflects the seven patients who died.
LVEDD  left ventricular end-diastolic diameter.
Table 5. Distribution of Shortening Fraction at the Baseline and
Final Evaluations
SF
Symptomatic Asymptomatic
Baseline Final Baseline Final
n n n n
 0.25 2 5 0 2
0.25–0.29 9 2 3 8
 0.30 26 23 35 28
Total 37* 30* 38 38
*The difference reflects the seven patients who died.
SF  shortening fraction.
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In particular, older age has previously been reported as an
index (29–32) of poor prognosis. Our findings support and
strengthen this concept (Table 1), as the age of symptomatic
patients was 20% higher than the age of asymptomatic
ones.
According to the ACC/AHA guidelines (19), surgical
indication when there is manifestation of FC II without
ventricular dysfunction is Class IIa. Klodas et al. (29)
reported in patients with average age of 50 years, that FC II
(New York Heart Association) heart failure should be
indicative for surgery. As a result, FC II patients had a
better postsurgical prognosis than those with FC III/IV.
We observed a lower mortality rate than Klodas et al. (29),
who reported 82% survival in patients with FC I/II and 45%
in those with FC III/IV. In our study, survival in patients
with FC I/II was 100% (Fig. 2) and, in patients with
symptoms, 82%. The difference in these mortality rates
probably reflects differences in the populations studied,
mainly regarding the etiology of AR and mean patient age,
in a likely parallel with LV overload duration.
The 90.6% survival rate and relatively normal LV func-
tion observed at the end of our 10-year study is consistent
with results reported by other authors (3,29,33).
The marked LV remodeling observed postoperatively
further validates the recognition of progression to FC III or
the manifestation of angina pectoris as cardinal signs of the
need for surgery. Overall, the low incidence of complica-
tions and the homogeneous return to degree FC I/II heart
failure give larger credence to this observation. This indi-
cation is shared with the ACC/AHA valve disease guide-
lines (19).
Survival and mortality. It is noteworthy that, even with a
high LVEDD (73 8.3 mm) at the beginning of the study,
half (51%) of the asymptomatic patients experienced a
natural evolution similar to that reported by Bonow et al.
(3). Similarly, in both studies the excellent evolution of
patients with severe AR, as long as normal function was
present, emphasizes the findings that irreversible LV dys-
function preceding symptoms is infrequent. Similar behav-
ior has been described in the literature (2,3,19), where the
frequency of sudden death during the natural evolution of
AR is reportedly only 0.2% per year.
The higher mortality in the symptomatic patients reflects
in part the presence of a valvular prosthesis. In fact, all
postsurgery complications as well four of the seven deaths
resulted from prosthesis dysfunction caused by endocarditis,
thrombosis, or failure. It is interesting to stress that there
were no postoperative deaths due to heart failure. The
remaining three patients died within six months of the onset
of symptoms while awaiting surgery. These data indicate
that surgery must be performed immediately after the
development of symptoms.
Our study identified three outcomes of the implanted
prostheses: 1) normal morphology in 49% (85% bioprosthe-
ses and 15% metallic prosthesis); 2) severe prosthesis dys-
function in 20% (6 patients); and 3) mild prosthesis dys-
function in 31% (9 patients).
Because of our patients’ poor socioeconomic status and
difficulties in adequate anticoagulation, bioprostheses were
preferred over metallic prostheses, leading to better quality
of life.
The present study was started before the use of vasodi-
lators was introduced, and none of our asymptomatic
patients received vasodilators. Therefore, it should be kept
in mind that use of vasodilators could affect the reliability of
symptoms as markers for therapy.
Ventricular function. The strategy proposed by the
present study effectively reduced eccentric hypertrophy.
Seventy percent of the survivors versus none at baseline in
the symptomatic groups had a final LVEDD60 mm (90%
 70 mm). Similarly, 30 survivors in the symptomatic group
had a final LVESD 40 mm.
Our data agree with data reported by Fioretti et al. (20)
and Daniel et al. (21), that is, there is a weak relationship
between laboratory criteria and postsurgical evolution. The
four patients who died after surgical correction demon-
Table 7. Distribution of the EF r-ex at the Baseline and
Final Evaluations
EF r-ex
Symptomatic Asymptomatic
Baseline Final Baseline Final
n n n n
 0 16 5 8 15
0–0.04 9 6 11 11
 0.05 10 19 17 11
Total 35* 30*† 36* 37*
*Four patients were unable to perform the tests at the baseline evaluation and one was
unable to perform the tests at the final evaluation; †The difference reflects the seven
patients who died.
EF r-ex  percentile variation of the rest-exercise left ventricular ejection
fraction (LVEF).
Table 8. Mortality Before Surgery
Patient
No.
LVEDD
(mm)
LVESD
(mm) SF LVEF Symptoms
1 80 54 0.33 0.58 FC III refused surgery
2 72 48 0.33 0.68 Syncope
3 77 48 0.38 0.58 FC III/IV
FC  functional class; LVEDD  left ventricular end-diastolic diameter; LVEF 
left ventricular ejection fraction; LVESD  left ventricular end-systolic diameter; SF
 shortening fraction.
Table 9. Cardiac Imaging Parameters for Four Patients Who
Died During the Late Postoperative Period
Baseline
Evaluation
Final
Evaluation*
LVEDD (mm) 77  4 52  0.5
LVESD (mm) 52  4 35  0.5
SF 0.32  0.04 0.32  0.01
LVEF 0.54  0.09 0.51  0.04
EF r-ex 1.2  10 7.1  12
*The mean interval between surgery and the final evaluation was 1.97  1.18 years.
LVEDD  left ventricular end-diastolic diameter; LVEF  left ventricular
ejection fraction; LVESD  left ventricular end-systolic diameter; SF  shortening
fraction; V/MI  volume-mass index; EF r-ex  percentile variation of the
rest-exercise LVEF.
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strated similar involution of cardiac diameters, and their
deaths were due to prosthesis-related complications.
An LVESD 50 mm was associated with a 76% chance
of experiencing symptoms, which is a five-fold increase
versus that associated with a LVESD 50 mm.
Furthermore, our data show that asymptomatic patients
with AR with normal ventricular function can be safely
followed clinically even after developing values of LVEDD
75 mm or LVESD 55 mm—a class IIa indication for
valve replacement according to the ACC/AHA guidelines
(19). In the 27 patients who had LVEDD 75 mm or
LVESD55 mm (Tables 3 and 4), 20 were followed for an
average of four years before needing surgery on the basis of
symptom development, with no further deterioration of LV
function at this time. The other seven patients remained
asymptomatic with normal ventricular function at the end of
the 10-year follow-up.
The rest-exercise variation in LVEF (EF r-ex) in our
study was dissociated from clinical symptoms (17). With a
cutoff value for EF r-ex of 0.05, 22.2% of the asymptom-
atic patients had a negative EF r-ex at baseline (decrease of
LVEF at exercise).
Contrary to what occurs in other cardiopathies, the fall in
the LVEF during exercise does not seem to signify intrinsic
myocardial dysfunction or loss of cardiac reserve, as initially
reported by Borer et al. (17). The LVEF at exercise tends to
decrease with the natural evolution of AR, without a change
in FC. Possibly such behavior does not necessarily reflect
actual reduction in the cardiac reserve, because we found an
increased variation of the index (0.05) in symptomatic
patients at the final evaluation (34,35).
In conclusion, our study showed that in a population of
younger patients with higher prevalence of rheumatic fever,
the indication for valve replacement based on the onset of
clinical symptoms was associated with a favorable outcome.
These results reinforce the class I indications of the ACC/
AHA guidelines and provide further basis for clinical
decision-making in class IIa indications. In the latter cases,
we showed that the indication for AVR based on the onset
of clinical symptoms rather than on specific values of LV
dimensions might be more appropriate for such population.
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